Tiziana Life Sciences PLC (NASDAQ:TLSA) shares were up 2.1% during mid-day trading on Tuesday . The stock traded as high as $2.95 and last traded at $2.92. Approximately 134,036 shares traded hands during trading, a decline of 87% from the average daily volume of 1,027,457 shares. The stock had previously closed at $2.86.
Several equities analysts have recently issued reports on TLSA shares. Zacks Investment Research downgraded shares of Tiziana Life Sciences from a “buy” rating to a “hold” rating in a report on Tuesday, February 23rd. B. Riley started coverage on shares of Tiziana Life Sciences in a report on Tuesday, December 22nd. They set a “buy” rating and a $8.00 price objective on the stock.
The stock has a 50-day moving average of $3.05 and a 200 day moving average of $3.21. The stock has a market cap of $181.74 million, a PE ratio of -94.33 and a beta of 1.41.
About Tiziana Life Sciences (NASDAQ:TLSA)
Tiziana Life Sciences Plc is a biotechnology company, which engages in the research and development of biotechnological and pharmaceutical products. Its lead product candidate in immunology is Foralumab (TZLS-401), which is a fully human anti-CD3 monoclonal antibody. The company was founded by Gabriele Marco Antonio Cerrone on November 4, 2013 and is headquartered in London, the United Kingdom.
See Also: Hedge Funds Explained
Receive News & Ratings for Tiziana Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tiziana Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.